Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation
Authors:
- Kazuma YamakawaKazuma Yamakawa
- Mineji HayakawaMHMineji Hayakawa
- Japan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study groupJGJapan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study group
- 1 January 2016
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 115 (06) , 1157-1166
Abstract
Summary: Recombinant human soluble thrombomodulin (rhTM) is a novel class of anticoagulants for treating disseminated intravascular coagulation (DIC). Although rhTM is widely used in clinical settings throughout Japan, there is limited clinical evidence supporting the use of rhTM in patients with sepsis-induced DIC. Furthermore, rhTM is not approved for DIC treatment in other countries. This study aimed to clarify the survival benefits of rhTM administration in critically ill patients. Data from 3,195 consecutive adult patients who were admitted to 42 intensive care units for the treatment of severe sepsis or septic shock between January 2011 and December 2013 were retrospectively analysed, and 1,784 patients were diagnosed with DIC based on the scoring algorithm from the Japanese Association for Acute Medicine DIC (n = 645, rhTM group; n = 1,139, control group). Propensity score matching created 452 matched pairs, and logistic regression analysis revealed a significant association between rhTM administration and lower in-hospital all-cause mortality in the propensity score-matched groups (odds ratio, 0.757; 95 % confidence interval, 0.574–0.999, p = 0.049). Inverse probability of treatment weighted and quintile-stratified analyses also revealed significant associations between rhTM administration and lower in-hospital all-cause mortality. Survival time in the propensity score-matched rhTM group was significantly longer than that in the propensity score-matched control group (hazard ratio, 0.781; 95 % confidence interval, 0.624–0.977, p = 0.03). Bleeding complications were not more frequent in the rhTM groups. In conclusion, this study demonstrated that rhTM administration is associated with reduced in-hospital all-cause mortality among patients with sepsis-induced DIC.Keywords
This publication has 31 references indexed in Scilit:
- Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis‐associated disseminated intravascular coagulation: an observational nationwide studyJournal of Thrombosis and Haemostasis, 2014
- Addition of recommendations for the use of recombinant human thrombomodulin to the “Expert consensus for the treatment of disseminated intravascular coagulation in Japan”Thrombosis Research, 2014
- Anticoagulant therapy for sepsis‐associated disseminated intravascular coagulation: the view from JapanJournal of Thrombosis and Haemostasis, 2014
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*Critical Care Medicine, 2013
- Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysisIntensive Care Medicine, 2013
- Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control studyCritical Care, 2011
- THROMBOMODULIN ALFA IN THE TREATMENT OF INFECTIOUS PATIENTS COMPLICATED BY DISSEMINATED INTRAVASCULAR COAGULATIONShock, 2011
- Regulation of inflammation by the protein C systemCritical Care Medicine, 2010
- Expert consensus for the treatment of disseminated intravascular coagulation in JapanThrombosis Research, 2010
- Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trialJournal of Thrombosis and Haemostasis, 2006